Serum c-erbB-2 oncoprotein in the diagnosis of gastric cancer in comparison with CA 19-9, CEA, TPA, CA 125 and AFP.

C. L. Perng, H. J. Lin, S. D. Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND. Although many tumor markers can detect gastric cancer, they are still far from perfect. The aim of this study was to evaluate the role of a new tumor marker, serum c-erbB-2 oncoprotein, in patients with gastric cancer. METHODS. We tested this tumor marker in 35 patients of gastric cancer, 13 patients of hepatoma, 13 patients of colon cancer, 8 patients of lung cancer, and 22 patients without malignancy (4 of acute pancreatitis, 10 of benign gastric ulcer and 8 normal subjects) between July and December 1991. A newly developed enzyme immunoassay kit was used to assay serum c-erbB-2 oncoprotein. RESULTS. Abnormal level of c-erbB-2 oncoprotein was found in 11/32 (34.4%) of gastric cancer, 4/13 (30.8%) of hepatoma, 2/8 (25%) of lung cancer, 3/13 (23.1%) of colon cancer, 0/3 (0%) of gastric lymphoma, and 4 of non-malignant conditions (18.2%). Six tumor markers were assessed at the same time in 32 patients of gastric cancer. The abnormal level for CA 19-9 was found in 13/32 patients (40.6%); for TPA: 9/32 (28.1%); for c-erbB-2 oncoprotein: 11/32 (34.4%); for CEA: 8/32 (25%); for CA 125: 2/32 (6.3%); and for AFP: 1/32 (3.1%). CONCLUSIONS. C-erbB-2 oncoprotein is a new tumor marker. Practical application needs further mass survey.

Original languageEnglish
Pages (from-to)82-86
Number of pages5
JournalChinese Medical Journal (Taipei)
Volume54
Issue number2
Publication statusPublished - Aug 1994
Externally publishedYes

Fingerprint

Oncogene Proteins
Stomach Neoplasms
Tumor Biomarkers
Serum
Colonic Neoplasms
Hepatocellular Carcinoma
Lung Neoplasms
Stomach Ulcer
Immunoenzyme Techniques
Pancreatitis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Serum c-erbB-2 oncoprotein in the diagnosis of gastric cancer in comparison with CA 19-9, CEA, TPA, CA 125 and AFP. / Perng, C. L.; Lin, H. J.; Lee, S. D.

In: Chinese Medical Journal (Taipei), Vol. 54, No. 2, 08.1994, p. 82-86.

Research output: Contribution to journalArticle

@article{f6ef6b86e839476a99e0289744a2bb22,
title = "Serum c-erbB-2 oncoprotein in the diagnosis of gastric cancer in comparison with CA 19-9, CEA, TPA, CA 125 and AFP.",
abstract = "BACKGROUND. Although many tumor markers can detect gastric cancer, they are still far from perfect. The aim of this study was to evaluate the role of a new tumor marker, serum c-erbB-2 oncoprotein, in patients with gastric cancer. METHODS. We tested this tumor marker in 35 patients of gastric cancer, 13 patients of hepatoma, 13 patients of colon cancer, 8 patients of lung cancer, and 22 patients without malignancy (4 of acute pancreatitis, 10 of benign gastric ulcer and 8 normal subjects) between July and December 1991. A newly developed enzyme immunoassay kit was used to assay serum c-erbB-2 oncoprotein. RESULTS. Abnormal level of c-erbB-2 oncoprotein was found in 11/32 (34.4{\%}) of gastric cancer, 4/13 (30.8{\%}) of hepatoma, 2/8 (25{\%}) of lung cancer, 3/13 (23.1{\%}) of colon cancer, 0/3 (0{\%}) of gastric lymphoma, and 4 of non-malignant conditions (18.2{\%}). Six tumor markers were assessed at the same time in 32 patients of gastric cancer. The abnormal level for CA 19-9 was found in 13/32 patients (40.6{\%}); for TPA: 9/32 (28.1{\%}); for c-erbB-2 oncoprotein: 11/32 (34.4{\%}); for CEA: 8/32 (25{\%}); for CA 125: 2/32 (6.3{\%}); and for AFP: 1/32 (3.1{\%}). CONCLUSIONS. C-erbB-2 oncoprotein is a new tumor marker. Practical application needs further mass survey.",
author = "Perng, {C. L.} and Lin, {H. J.} and Lee, {S. D.}",
year = "1994",
month = "8",
language = "English",
volume = "54",
pages = "82--86",
journal = "Journal of the Chinese Medical Association",
issn = "1726-4901",
publisher = "Elsevier Taiwan LLC",
number = "2",

}

TY - JOUR

T1 - Serum c-erbB-2 oncoprotein in the diagnosis of gastric cancer in comparison with CA 19-9, CEA, TPA, CA 125 and AFP.

AU - Perng, C. L.

AU - Lin, H. J.

AU - Lee, S. D.

PY - 1994/8

Y1 - 1994/8

N2 - BACKGROUND. Although many tumor markers can detect gastric cancer, they are still far from perfect. The aim of this study was to evaluate the role of a new tumor marker, serum c-erbB-2 oncoprotein, in patients with gastric cancer. METHODS. We tested this tumor marker in 35 patients of gastric cancer, 13 patients of hepatoma, 13 patients of colon cancer, 8 patients of lung cancer, and 22 patients without malignancy (4 of acute pancreatitis, 10 of benign gastric ulcer and 8 normal subjects) between July and December 1991. A newly developed enzyme immunoassay kit was used to assay serum c-erbB-2 oncoprotein. RESULTS. Abnormal level of c-erbB-2 oncoprotein was found in 11/32 (34.4%) of gastric cancer, 4/13 (30.8%) of hepatoma, 2/8 (25%) of lung cancer, 3/13 (23.1%) of colon cancer, 0/3 (0%) of gastric lymphoma, and 4 of non-malignant conditions (18.2%). Six tumor markers were assessed at the same time in 32 patients of gastric cancer. The abnormal level for CA 19-9 was found in 13/32 patients (40.6%); for TPA: 9/32 (28.1%); for c-erbB-2 oncoprotein: 11/32 (34.4%); for CEA: 8/32 (25%); for CA 125: 2/32 (6.3%); and for AFP: 1/32 (3.1%). CONCLUSIONS. C-erbB-2 oncoprotein is a new tumor marker. Practical application needs further mass survey.

AB - BACKGROUND. Although many tumor markers can detect gastric cancer, they are still far from perfect. The aim of this study was to evaluate the role of a new tumor marker, serum c-erbB-2 oncoprotein, in patients with gastric cancer. METHODS. We tested this tumor marker in 35 patients of gastric cancer, 13 patients of hepatoma, 13 patients of colon cancer, 8 patients of lung cancer, and 22 patients without malignancy (4 of acute pancreatitis, 10 of benign gastric ulcer and 8 normal subjects) between July and December 1991. A newly developed enzyme immunoassay kit was used to assay serum c-erbB-2 oncoprotein. RESULTS. Abnormal level of c-erbB-2 oncoprotein was found in 11/32 (34.4%) of gastric cancer, 4/13 (30.8%) of hepatoma, 2/8 (25%) of lung cancer, 3/13 (23.1%) of colon cancer, 0/3 (0%) of gastric lymphoma, and 4 of non-malignant conditions (18.2%). Six tumor markers were assessed at the same time in 32 patients of gastric cancer. The abnormal level for CA 19-9 was found in 13/32 patients (40.6%); for TPA: 9/32 (28.1%); for c-erbB-2 oncoprotein: 11/32 (34.4%); for CEA: 8/32 (25%); for CA 125: 2/32 (6.3%); and for AFP: 1/32 (3.1%). CONCLUSIONS. C-erbB-2 oncoprotein is a new tumor marker. Practical application needs further mass survey.

UR - http://www.scopus.com/inward/record.url?scp=0028487850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028487850&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 82

EP - 86

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

SN - 1726-4901

IS - 2

ER -